These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1909485)

  • 41. Terguride in fluctuating parkinsonian patients: a double-blind study versus placebo.
    Pacchetti C; Martignoni E; Bruggi P; Godi L; Aufdembrinke B; Miltenburger C; Voet B; Nappi G
    Mov Disord; 1993 Oct; 8(4):463-5. PubMed ID: 7901760
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Selegiline as a primary treatment of Parkinson's disease.
    Myllylä VV; Sotaniemi KA; Vuorinen JA; Heinonen EH
    Acta Neurol Scand Suppl; 1991; 136():70-2. PubMed ID: 1801540
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition.
    Clarke A; Johnson ES; Mallard N; Corn TH; Johnston A; Boyce M; Warrington S; MacMahon DG
    J Neural Transm (Vienna); 2003 Nov; 110(11):1257-71. PubMed ID: 14628190
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Randomized study during a year of early combination of L-dopa/lisuride in Parkinson disease].
    Vermersch P; Fondarai J; Petit H
    Therapie; 1991; 46(6):481-6. PubMed ID: 1819154
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.
    NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators
    Lancet Neurol; 2015 Aug; 14(8):795-803. PubMed ID: 26116315
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.
    Olanow CW; Myllylä VV; Sotaniemi KA; Larsen JP; Pålhagen S; Przuntek H; Heinonen EH; Kilkku O; Lammintausta R; Mäki-Ikola O; Rinne UK
    Neurology; 1998 Sep; 51(3):825-30. PubMed ID: 9748034
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Selegiline in de novo parkinsonian patients: the Finnish study.
    Myllylä VV; Sotaniemi KA; Vuorinen JA; Heinonen EH
    Mov Disord; 1993; 8 Suppl 1():S41-4. PubMed ID: 8302307
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
    Korczyn AD; Brooks DJ; Brunt ER; Poewe WH; Rascol O; Stocchi F
    Mov Disord; 1998 Jan; 13(1):46-51. PubMed ID: 9452325
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of selegiline (deprenyl) on cognition in early Parkinson's disease.
    Dalrymple-Alford JC; Jamieson CF; Donaldson IM
    Clin Neuropharmacol; 1995 Aug; 18(4):348-59. PubMed ID: 8665548
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chronic s.c. lisuride in Parkinson's disease--motor-performance and avoidance of psychiatric side effects.
    Bittkau S; Przuntek H
    J Neural Transm Suppl; 1988; 27():35-54. PubMed ID: 3165438
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lisuride infusion pump for Parkinson's disease.
    Lancet; 1986 Aug; 2(8502):348-9. PubMed ID: 2874360
    [No Abstract]   [Full Text] [Related]  

  • 52. Selegiline slows the progression of the symptoms of Parkinson disease.
    Pålhagen S; Heinonen E; Hägglund J; Kaugesaar T; Mäki-Ikola O; Palm R;
    Neurology; 2006 Apr; 66(8):1200-6. PubMed ID: 16540603
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Long-term selegiline tolerance in the treatment of Parkinson's disease].
    Vermersch P; Petit H
    Therapie; 1992; 47(1):75-8. PubMed ID: 1523599
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease.
    Golbe LI
    Neurology; 1989 Aug; 39(8):1109-11. PubMed ID: 2503769
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Selegiline use to prevent progression of Parkinson's disease. Experience in 22 de novo patients.
    Elizan TS; Yahr MD; Moros DA; Mendoza MR; Pang S; Bodian CA
    Arch Neurol; 1989 Dec; 46(12):1275-9. PubMed ID: 2511824
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of selegiline (deprenyl) on the progression of disability in early Parkinson's disease. Parkinson Study Group.
    Shults CW
    Acta Neurol Scand Suppl; 1993; 146():36-42. PubMed ID: 8333252
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients.
    Elizan TS; Yahr MD; Moros DA; Mendoza MR; Pang S; Bodian CA
    Arch Neurol; 1989 Dec; 46(12):1280-3. PubMed ID: 2511825
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lisuride infusion pump in Parkinson's disease. A report of two cases.
    Gershanik OS; Scipioni O; García S
    J Neural Transm Suppl; 1988; 27():85-90. PubMed ID: 2969955
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial.
    Allain H; Pollak P; Neukirch HC
    Mov Disord; 1993; 8 Suppl 1():S36-40. PubMed ID: 8302306
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
    Lees AJ
    BMJ; 1995 Dec; 311(7020):1602-7. PubMed ID: 8555803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.